SAB Biotherapeutics, Inc.
SABS
$2.19
$0.13956.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -8.63% | 0.07% | |||
| Gross Profit | 8.63% | -1.60% | |||
| SG&A Expenses | -12.18% | 26.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.65% | 6.41% | |||
| Operating Income | 9.65% | -7.63% | |||
| Income Before Tax | -94.63% | 54.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -94.63% | 54.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -94.63% | 54.39% | |||
| EBIT | 9.65% | -7.63% | |||
| EBITDA | 10.37% | -8.36% | |||
| EPS Basic | -94.56% | 54.39% | |||
| Normalized Basic EPS | -94.54% | 54.49% | |||
| EPS Diluted | -94.56% | 54.39% | |||
| Normalized Diluted EPS | -94.54% | 54.49% | |||
| Average Basic Shares Outstanding | 0.03% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||